ClinicalTrials.gg
CompletedNCT06467084KONFIDENT-KIDUpdated Aug 5, 2026Results posted

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

A Phase 3 interventional study of KVD900 150 mg and KVD900 300 mg in Hereditary Angioedema, sponsored by KalVista Pharmaceuticals, Ltd.. Completed at 24 sites in 7 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by KalVista Pharmaceuticals, Ltd. (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · Chiesi Farmaceutici S.p.A..

Started
2024
the only one that year
Phase 3
4 of 12
none open now
Registered
8th of 12
by date

Among the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2024, is one of 4 in phase 3, and was the 8th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • KONFIDENT-KID
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients 2 to 11 years of age.
  2. Confirmed diagnosis of HAE Type I or II.
  3. For patients ≥20 kg at screening, patient has had at least 1 documented HAE attack in the last year prior to screening.
  4. Caregiver, as assessed by the Investigator, must be able to appropriately store and administer IMP and be able to read, understand, and complete the diary.
  5. Investigator believes that the patient and caregiver are willing and able to adhere to all protocol requirements.
  6. Parent or Legally Authorized Representative (LAR) provides signed and patient provides assent (when applicable).

Exclusion criteria

Exclusion Criteria:

  1. Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH, idiopathic angioedema, or angioedema associated with urticaria.
  2. A history of poor response to bradykinin receptor 2 blocker, C1-INH therapy, or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator.
  3. Patient weighs \<9.5 kg.
  4. Use of angiotensin-converting enzyme inhibitors after the Screening Visit.
  5. Any estrogen-containing medications with systemic absorption (such as oral including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the Screening Visit.
  6. Patients who require sustained use of strong cytochrome P450 3A4 () inhibitors or inducers or moderate CYP3A4 inducers.
  7. Any clinically significant comorbidity or systemic dysfunction, which in the opinion of the Investigator, would jeopardize the safety of the patient by participating in the trial.
  8. Known to sebetralstat or to any of the .
  9. Participation in any interventional clinical trial within 4 weeks of the last dosing of investigational drug prior to the Screening Visit.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Other
    150 mg Dose Group

    Patients will take a single 150 mg dose of KVD900.

    Drug: KVD900 150 mg

  • Other
    300 mg Dose Group

    Patients will take a single 300 mg dose of KVD900.

    Drug: KVD900 300 mg

  • Other
    600 mg Dose Group

    Patients will take a single 600 mg dose of KVD900.

    Drug: KVD900 600 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE was defined as an adverse event (AE) that met any of the following conditions: (1) began on or after the first dose of IMP, (2) began before the first dose of IMP and increased in severity on or after first dose, (3) was completely missing a start date and the stop date, (4) was completely missing a start date and the stop date was on or after the first dose of IMP. An on-treatment TEAE was defined as any TEAE occurring within 3 days of IMP administration. A treatment-related TEAE was an AE considered related to the IMP by the investigator. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in-patient hospitalization or prolongation, resulted in significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event (based upon medical and scientific judgment).

    Time frame: From first dose of IMP until the Final/Early Termination (ET) Visit, up to a maximum of 54 weeks.

Secondary outcomes

  1. Plasma Concentrations of Sebetralstat

    During the Enrollment Visit, participants were dosed with IMP (sebetralstat 300 mg ED) and monitored for tolerability. Pharmacokinetic (PK) samples were collected via venous access or capillary collection (eg, finger prick) at specified timepoints. For participants enrolled under protocol v3.4 who received sebetralstat 600 mg ED, a second PK assessment was performed at the Dose Increase Visit. The Dose Increase Visit occurred as soon as possible after implementation of the protocol amendment and could occur at any time during the participant's participation in the trial.

    Time frame: At 0.5 hours (±5 min), 2 hours (±15 min), and 4 hours (±15 min) post-dose. PK assessments for sebetralstat 300 mg ED were conducted at the Enrollment Visit, and for 600 mg ED at the Dose Increase Visit (up to 12.6 months after Enrollment Visit).

07

Results

Posted Aug 5, 2026

Participant flow

Pediatric participants (aged 2 to 11 years) with hereditary angioedema (HAE) Type I or II were enrolled at trial sites in Canada, Germany, France, Israel, Italy, Japan, and the United States (US). Participants enrolled under protocol v1.0 to v3.3 received sebetralstat 300 mg equivalent dosing (ED). Following a US-specific protocol amendment, dose levels were increased; US-only participants who continued under protocol v3.4 had a Dose Increase Visit and received sebetralstat 600 mg ED thereafter.

Participant flow — Overall Study
MilestoneWeight Group ≥9.5 to <20 kgWeight Group ≥20 to ≤45 kgWeight Group ≥45 kg
Started3276
Received sebetralstat 300 mg ed (protocol v1.0 - 3.3)3276
Received sebetralstat 600 mg ed (protocol v3.4; us only)061
Completed3253
Not completed023
Withdrew: Lost to follow-up011
Withdrew: Withdrawal by subject012

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE was defined as an adverse event (AE) that met any of the following conditions: (1) began on or after the first dose of IMP, (2) began before the first dose of IMP and increased in severity on or after first dose, (3) was completely missing a start date and the stop date, (4) was completely missing a start date and the stop date was on or after the first dose of IMP. An on-treatment TEAE was defined as any TEAE occurring within 3 days of IMP administration. A treatment-related TEAE was an AE considered related to the IMP by the investigator. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in-patient hospitalization or prolongation, resulted in significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event (based upon medical and scientific judgment).

Time frame:
From first dose of IMP until the Final/Early Termination (ET) Visit, up to a maximum of 54 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsSebetralstat 300 mg EDSebetralstat 600 mg ED
Any TEAE201
Any treatment-related TEAE00
Any on-treatment TEAE111
Any serious TEAE00
SecondaryPlasma Concentrations of Sebetralstat

During the Enrollment Visit, participants were dosed with IMP (sebetralstat 300 mg ED) and monitored for tolerability. Pharmacokinetic (PK) samples were collected via venous access or capillary collection (eg, finger prick) at specified timepoints. For participants enrolled under protocol v3.4 who received sebetralstat 600 mg ED, a second PK assessment was performed at the Dose Increase Visit. The Dose Increase Visit occurred as soon as possible after implementation of the protocol amendment and could occur at any time during the participant's participation in the trial.

Time frame:
At 0.5 hours (±5 min), 2 hours (±15 min), and 4 hours (±15 min) post-dose. PK assessments for sebetralstat 300 mg ED were conducted at the Enrollment Visit, and for 600 mg ED at the Dose Increase Visit (up to 12.6 months after Enrollment Visit).
Reported as:
Mean · ng/mL
Plasma Concentrations of Sebetralstat
ng/mLSebetralstat 300 mg EDSebetralstat 600 mg ED
0.5 hours post-dose1786.00 ± 1263.6904042.86 ± 1843.056
2 hours post-dose1145.59 ± 775.5942761.33 ± 1090.667
4 hours post-dose601.05 ± 1103.278953.57 ± 563.929
Post-hocMaximum Concentration (Cmax) of Sebetralstat

During the Enrollment Visit, participants were dosed with IMP (sebetralstat 300 mg ED) and monitored for tolerability. PK samples were collected via venous access or capillary collection (eg, finger prick) at specified timepoints. For participants enrolled under protocol v3.4 who received sebetralstat 600 mg ED, a second PK assessment was performed at the Dose Increase Visit. The Dose Increase Visit occurred as soon as possible after implementation of the protocol amendment and could occur at any time during the participant's participation in the trial. A final population-based PK model of sebetralstat was utilized to obtain individual post hoc estimates of PK parameters. For participants with measurable plasma concentrations of sebetralstat, Cmax was predicted using individual post hoc PK parameter estimates.

Time frame:
At 0.5 hours (±5 min), 2 hours (±15 min), and 4 hours (±15 min) post-dose. PK assessments for sebetralstat 300 mg ED were conducted at the Enrollment Visit, and for 600 mg ED at the Dose Increase Visit (up to 12.6 months after Enrollment Visit).
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax) of Sebetralstat
ng/mLSebetralstat 300 mg EDSebetralstat 600 mg ED
Maximum Concentration (Cmax) of Sebetralstat2010 ± 42.94690 ± 30.5
Post-hocArea Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Sebetralstat

During the Enrollment Visit, participants were dosed with IMP (sebetralstat 300 mg ED) and monitored for tolerability. PK samples were collected via venous access or capillary collection (eg, finger prick) at specified timepoints. For participants enrolled under protocol v3.4 who received sebetralstat 600 mg ED, a second PK assessment was performed at the Dose Increase Visit. The Dose Increase Visit occurred as soon as possible after implementation of the protocol amendment and could occur at any time during the participant's participation in the trial. A final population-based PK model of sebetralstat was utilized to obtain individual post hoc estimates of PK parameters. For participants with measurable plasma concentrations of sebetralstat, AUC0-inf was predicted using individual post hoc PK parameter estimates.

Time frame:
At 0.5 hours (±5 min), 2 hours (±15 min), and 4 hours (±15 min) post-dose. PK assessments for sebetralstat 300 mg ED were conducted at the Enrollment Visit, and for 600 mg ED at the Dose Increase Visit (up to 12.6 months after Enrollment Visit).
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Sebetralstat
ng*h/mLSebetralstat 300 mg EDSebetralstat 600 mg ED
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Sebetralstat5350 ± 53.111660 ± 29.8

Adverse events

Collected over For all-cause mortality reporting, from enrollment until the Final/ET Visit; up to a maximum of 76 weeks for overall duration of trial. For AE reporting, from first dose of IMP until the Final/ET Visit, up to a maximum of 54 weeks. All-cause mortality is reported for all participants enrolled in the trial. Serious and Other AEs are reported for all participants who received at least 1 dose of IMP.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sebetralstat 300 mg ED0/36 (0%)0/36 (0%)20/36 (55.6%)
Sebetralstat 600 mg ED0/7 (0%)0/7 (0%)1/7 (14.3%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventSebetralstat 300 mg EDSebetralstat 600 mg ED
NauseaGastrointestinal disorders0/361/7
ParaesthesiaNervous system disorders0/361/7
NasopharyngitisInfections and infestations5/360/7
Upper respiratory tract infectionInfections and infestations5/360/7
Abdominal pain upperGastrointestinal disorders4/360/7
VomitingGastrointestinal disorders4/360/7
HeadacheNervous system disorders4/360/7
Ear infectionInfections and infestations2/360/7
Gastrointestinal infectionInfections and infestations2/360/7
InfluenzaInfections and infestations2/360/7

Baseline characteristics

The Safety Set (SAF) included all participants who received at least 1 dose of IMP.

Age, Continuous
Age, Continuous(years)Weight Group ≥9.5 to <20 kgWeight Group ≥20 to ≤45 kgWeight Group ≥45 kgTotal
Median5.0 (4 to 5)8.0 (6 to 11)9.5 (8 to 10)8.0 (4 to 11)
Age, Customized
Age, Customized(Participants)Weight Group ≥9.5 to <20 kgWeight Group ≥20 to ≤45 kgWeight Group ≥45 kgTotal
2 - 5 years3003
6 - 11 years027633
Sex: Female, Male
Sex: Female, Male(Participants)Weight Group ≥9.5 to <20 kgWeight Group ≥20 to ≤45 kgWeight Group ≥45 kgTotal
Female213318
Male114318
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Weight Group ≥9.5 to <20 kgWeight Group ≥20 to ≤45 kgWeight Group ≥45 kgTotal
Hispanic or Latino0101
Not Hispanic or Latino321529
Unknown or Not Reported0516
Race
Race(Participants)Weight Group ≥9.5 to <20 kgWeight Group ≥20 to ≤45 kgWeight Group ≥45 kgTotal
American Indian or Alaska Native0011
Asian0112
Black0101
Native Hawaiian or Pacific islander0000
White320326
Other0101
Not Reported0415
08

Study locations

24 sites
  • KalVista Investigative Site
    Birmingham, Alabama 35209, United States
  • KalVista Investigative Site
    Scottsdale, Arizona 85251, United States
  • KalVista Investigative Site
    San Diego, California 92123, United States
  • KalVista Investigative Site
    Santa Monica, California 90404, United States
  • KalVista Investigative Site
    Evansville, Indiana 47715, United States
  • KalVista Investigative Site
    Wheaton, Maryland 20902, United States
  • KalVista Investigative Site
    St Louis, Missouri 63141, United States
  • KalVista Investigative Site
    Toledo, Ohio 43560, United States
  • KalVista Investigative Site
    Hershey, Pennsylvania 17011, United States
  • KalVista Investigative Site
    Dallas, Texas 75231, United States
  • KalVista Investigative Site
    Edmonton, Alberta T6G 2B7, Canada
  • KalVista Investigative Site
    Lille, 59000, France
  • KalVista Investigative Site
    Marseille, 13005, France
  • KalVista Investigative Site
    Paris, 75012, France
  • KalVista Investigative Site
    Frankfurt am Main, 60590, Germany
  • KalVista Investigative Site
    Frankfurt am Main, 60596, Germany
  • KalVista Investigative Site
    Haifa, 31048, Israel
  • KalVista Investigative Site
    Petah Tikva, 4920235, Israel
  • KalVista Investigative Site
    Tel Aviv, 6423906, Israel
  • KalVista Investigative Site
    Milan, 20097, Italy
  • KalVista Investigative Site
    Padova, 35128, Italy
  • KalVista Investigative Site
    Rome, 00133, Italy
  • KalVista Investigative Site
    Kawagoe, 350-8550, Japan
  • KalVista Investigative Site
    Tokyo, 113-8431, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data will not be shared until all global regulatory filings are complete.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jan 2026, 17 months.

Results were first posted in Aug 2026, 6 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 17 months is below that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2024
First posted
Jun 20, 2024
StartActual
Aug 1, 2024
Primary completionActual
Jan 15, 2026
CompletionActual
Jan 15, 2026
Results first posted
Aug 5, 2026
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06467084
Responsible party
Sponsor
First posted
Jun 20, 2024
Start date
Aug 1, 2024
Primary completion
Jan 15, 2026
Completion
Jan 15, 2026
Results posted
Aug 5, 2026
Last update
Aug 5, 2026

Study contacts

Study Director
study director · KalVista Pharmaceuticals, Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sebetralstat

Start the discussion